Latest news
NCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer - OncLiveOncLive · Mon, 03 Aug 2026 15:13:18 GMTGedatolisib/Fulvestrant Earns NCCN Category 1 Listing for HR+/HER2- Breast Cancer - CancerNetworkCancerNetwork · Mon, 03 Aug 2026 12:08:52 GMTNCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 15:09:03 GMT